Villard Christina, Abdelrafee Ahmed, Habib Miriam, Ndegwa Nelson, Jorns Carl, Sparrelid Ernesto, Allard Marc-Antoine, Adam René
Department of Transplantation Surgery, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
Gastrointestinal Surgery Center, Department of Surgery, Mansoura University, Mansoura, Egypt.
Eur J Surg Oncol. 2022 Dec;48(12):2432-2439. doi: 10.1016/j.ejso.2022.06.021. Epub 2022 Jun 21.
Metastatic spread of colorectal cancer to the liver impacts prognosis. Advances in chemotherapy have resulted in increased resectability rates and thereby improved survival in patients with colorectal liver metastases (CRLM). However, criteria are needed to ensure that patients selected for hepatic resection benefit from the invasive therapy. The study aimed to construct a predictive model for overall survival (OS) in patients with CRLM, based on preoperatively available information.
The retrospective cohort study reviewed all patients with CRLM discussed at multidisciplinary team conference at Karolinska University Hospital, Stockholm, Sweden, 2013-2018. Independent prognostic factors for OS were identified, based on which a score model was generated. The model was validated on patients treated for CRLM at Hôpital Universitaire Paul Brousse, Villejuif, France, 2007-2018. Calibration and discrimination methods were used for internal and external validation.
The Swedish development cohort included 1013 patients, the French validation cohort 391 patients. Poor OS was significantly associated with age>60years (hazard ratio (HR) 3.57 (95%CI 2.18-9.94)), number of CRLM (HR 4.59 (2.83-12.20)), diameter of largest CRLM>5 cm (HR 2.59 (1.74-5.03)), right-sided primary tumour (HR 2.98 (2.00-5.80)), extrahepatic disease (HR 4.14 (2.38-15.87)) and non-resectability (HR 0.77 (0.66-0.90)). The C-statistic for prediction of OS was .74, in the development cohort and 0.69 in the validation cohort.
The presented predictive score model can adequately predict OS for patients at the initial diagnosis of CRLM. The prognostic model could be of clinical value in the management of all patients with CRLM, by predicting individualized survival and thereby facilitating treatment recommendations.
结直肠癌肝转移影响预后。化疗进展提高了可切除率,从而改善了结直肠癌肝转移(CRLM)患者的生存率。然而,需要标准来确保选择接受肝切除的患者能从这种侵入性治疗中获益。本研究旨在基于术前可得信息构建CRLM患者总生存期(OS)的预测模型。
这项回顾性队列研究纳入了2013年至2018年在瑞典斯德哥尔摩卡罗林斯卡大学医院多学科团队会议上讨论的所有CRLM患者。确定了OS的独立预后因素,并据此生成了一个评分模型。该模型在法国维勒瑞夫保罗·布罗塞大学医院2007年至2018年接受CRLM治疗的患者中进行了验证。采用校准和鉴别方法进行内部和外部验证。
瑞典的开发队列包括1013例患者,法国的验证队列包括391例患者。OS较差与年龄>60岁(风险比(HR)3.57(95%CI 2.18 - 9.94))、CRLM数量(HR 4.59(2.83 - 12.20))、最大CRLM直径>5 cm(HR 2.59(1.74 - 5.03))、右侧原发性肿瘤(HR 2.98(2.00 - 5.80))、肝外疾病(HR 4.14(2.38 - 15.87))和不可切除性(HR 0.77(0.66 - 0.90))显著相关。开发队列中预测OS的C统计量为0.74,验证队列中为0.69。
所提出的预测评分模型能够充分预测CRLM初诊患者的OS。该预后模型通过预测个体生存情况并因此促进治疗建议,在所有CRLM患者的管理中可能具有临床价值。